跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
ABIRATERONE-TEVA FC TABLET 250 MG - HSA Drug Approval Details
Approvals
/
HSA
/
ABIRATERONE-TEVA FC TABLET 250 MG
Approved
THERAPEUTIC
ABIRATERONE-TEVA FC TABLET 250 MG
TEVA PHARMACEUTICAL INDUSTRIES LTD. (ISRAEL)
🇸🇬 Health Sciences Authority
Approval Date
Jan 8, 2022
Approval ID
5e5bd1ee72e97db0
Company
TEVA PHARMACEUTICAL INDUSTRIES LTD. (ISRAEL)
Type
Therapeutic
Approval Details
Approval Id
5e5bd1ee72e97db0
Drug Name
ABIRATERONE-TEVA FC TABLET 250 MG
Product Name
ABIRATERONE-TEVA FC TABLET 250 MG
Approval Number
SIN16416P
Approval Date
2022-01-08
Registrant
TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.
Licence Holder
TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.
Drug Type
Therapeutic
Forensic Classification
PRESCRIPTION ONLY MEDICINES
Dosage Form
TABLET, FILM COATED
Route Of Administration
ORAL
Atc Code
L02BX03
Atc Item Name
abiraterone
Pharma Manufacturer Name
TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.
Company Detail Path
/organization/teva-pharmaceutical-investments-singapore-pte-ltd
Active Ingredients
Abiraterone Acetate
250 mg
ABIRATERONE ACETATE
250 MG
Approved
Quick Info
Agency
HSA
Country
🇸🇬
Approval Date
Jan 8, 2022
Approval ID
5e5bd1ee72e97db0
Type
Therapeutic
Back to HSA Approvals